MassIVEapplication/xmlftp://massive-ftp.ucsd.edu/v05/MSV000092056/primaryOK2000000Birgit Schillinghttps://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=a172756fa86c4d64ab8331e58554add0bschilling@buckinstitute.orgMassIVE35MS:1002864 - No post-translational-modifications are included in the identified peptides of this datasetProteomicsOrbitrap EclipseMus Musculus (ncbitaxon:10090)Buck InstituteProteoglycan, other disease, PhrB photolyase activity, selection process, Neoplasms, paediatric, paediatric ulcerative colitis, Benign Neoplasm, Matrix, Gene, Ulcerative colitis (disorder), Spectrum Analyses, Tumor, photoreactivating enzyme activity, Matrices, pigmented epithelium, Inflammatory Bowel Disease, Malignant, Relative, unspecified, diseases, Roles, Taenia Coli, Appendix, Clinical Progression, Mass, Gene Products, disease or disorder, Proteoglycan Type H, Concepts, diseases and disorders, 3, tissue remodelling, stratum pigmentosa retinae, left-sided ulcerative colitis, NUP96, Analysis, colon inflammation, Ulcerative Colitis Type, Extracellular Matrices, pediatric ulcerative colitis, epithelium, Mass Spectroscopy, Progression, Mass Spectrum Analysis, average, treatment, Omental Appendix, human disease, matrisome, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Clinical, Malignancy, Analyses, PRECOCIOUS, Colitis Gravis, Tissue, pigmented retina, regional enteritis, posterior intestine, F23A5.3, free, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, non-neoplastic, Neoplasias, Clinical Course, malignant neoplasm, Extracellular, Role Concepts, Exacerbation, Therapies, disorder, Homo sapiens disease, Malignancies, Colitides, F23A5_3, Ulcerative colitis, Cancer, Tumors, Morbidities, Therapy, PRE, colitis, Disease, Malignant Neoplasm, Data Set, pediatric, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Proteins, disorders, Disease Exacerbation, inflammation of colon, Maps, Ulcerative Colitis, medical condition, ULCERATVE COLITIS UNSPCF, ulcerative colitis, Appendix Epiploica, Spectrum Analysis, inflammatory bowel disease (Crohn disease) 1, hindgut, Concept, Spectroscopy, colitis (disease), MODIFIER OF SNC1, disease management., MS, MT, Benign, large bowel, Role Concept, Other ulcerative colitis, retinal pigment, epithelial, Relative Risks, Protein, deoxyribonucleic photolyase activity, Neoplasm, Role, Crohn disease, dipyrimidine photolyase (photosensitive), condition, simple tissue, Omental Appendices, retinal pigment layer, Mass Spectrum Analyses, epitheliocyte, Relative Risk, Mass Spectrum, primary cancer, RPE, Risk, photolyase activity, susceptibility to, Risks, Spectrometry, Benign Neoplasms, Appendices, UC - ulcerative colitis, Cancers, Omental, malignant tumor, Treatments, Malignant Neoplasms, p. pigmentosa retinae, Protein Gene Products, Gene Proteins, disease, phr A photolyase activity, DNA-photoreactivating enzyme, Therapeutic, COLON, label, Idiopathic Proctocolitis, Treatment, deoxyribonucleate pyrimidine dimer lyase (photosensitive), Other ulcerative colitis (disorder), Neoplasia, Crohn disease-associated Growth failureMatrix, tissue remodelling., matrisome, Extracellular Matrices, Matrices, Extracellular0PXD042551falseExtracellular matrix orchestration of tissue remodelling during chronic colitisUlcerative colitis is a debilitating and recurrent condition with significant co-morbidities including risk of developing cancer and that is associated with extensive tissue remodeling that is both a consequence and mediator of disease progression. Here, label-free mass spectrometry was used to characterise extracellular matrix remodelling in a murine model of colitis. Unique proteomic profiles of the extracellular matrix landscape distinguished inflamed from matched-normal colon tissue thus identifying pre- and pathological colitic states that were predominantly differentiated by expression of proteoglycans. Network maps derived from this dataset highlighted a central role for matrisomal proteins in epithelial-stromal interactions and identified orchestrating nodes that could be exploited in selection of therapeutic targets.Tue May 30 16:06:00 BST 2023MSV000092056